Literature DB >> 1540407

The effect of cytokines and pharmacologic agents on chronic HIV infection.

G Poli1, A S Fauci.   

Abstract

The ability of the human immunodeficiency virus (HIV) to replicate in CD+ T lymphocytes and mononuclear phagocytes(MP) is strongly influenced by immunoregulatory cytokines. In the T cell system, interleukin-2 (IL-2) provides a mitogenic signal leading to both cell proliferation and virus replication. Among other HIV-inductive cytokines, only tumor necrosis factor-alpha or -beta (TNF-alpha/-beta) have been shown thus far to trigger virus expression both in T cells and MP. The mechanism of action of TNF involves the activation of the cellular transcription factor NF-kB which binds to specific consensus sequences present in the enhancer region of the HIV proviral LTR. In addition, several other cytokines (including colony stimulating factors, IL-1, IL-3, and IL-6) have demonstrated upregulatory effects on HIV production in MP, whereas nonimmune interferons (INF-alpha/-beta) have been shown to suppress HIV replication in T cells and MP by acting at different phases in the virus life cycle. Finally, cytokines such as TGF-beta, IFN-gamma, and IL-4 have demonstrated either upregulatory or suppressive effects on virus expression depending on the experimental conditions. This scenario indicates that HIV expression is under the control of a complex network of immunoregulatory cytokines, in addition to its own endogenous regulatory proteins, suggesting that new pharmacologic strategies may be aimed at either mimicking or interrupting cytokine-dependent virus expression. In this regard, a number of different physiologic and pharmacologic agents capable of interfering with cytokine-mediated events, including glucocorticoids, anti-oxidants, such as N-Acetyl-L-Cysteine (NAC), and retinoic acid (RA) have already been shown to profoundly affect HIV replication in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540407     DOI: 10.1089/aid.1992.8.191

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  61 in total

1.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

Review 2.  Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract.

Authors:  T Schneider; R Ullrich; M Zeitz
Journal:  Springer Semin Immunopathol       Date:  1997

Review 3.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.

Authors:  D Weissman; G Poli; A Bousseau; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

5.  Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Effect of pregnancy and human immunodeficiency virus infection on intracellular interleukin-2 production patterns.

Authors:  Madeline Y Sutton; Bart Holland; Thomas N Denny; Ambrosia Garcia; Zenaida Garcia; Dana Stein; Arlene D Bardeguez
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

7.  Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.

Authors:  S M Levitz; A Tabuni; S H Nong; D T Golenbock
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

8.  Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Authors:  S Makonkawkeyoon; R N Limson-Pobre; A L Moreira; V Schauf; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Clastogenic factors as potential biomarkers of increased superoxide production.

Authors:  Ingrid Emerit
Journal:  Biomark Insights       Date:  2007-12-11

10.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.

Authors:  M Adams; L Sharmeen; J Kimpton; J M Romeo; J V Garcia; B M Peterlin; M Groudine; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.